



ASX Release
17th October 2024

TRADING UPDATE – USA and Europe

Compumedics USA sales growth strategy delivers in Q1 FY25 numbers, Europe secures another major customer

BUSINESS Update

- USA business orders taken 136% higher than same time last year driven primarily by sleep and Somfit business
- Somfit sales close in on \$1m (USD0.6m) in the USA from a zero base this time last year
- The USA Q1 result builds on the H2 FY24 performance there and shows early signs of the Somfit business opportunity in this key market
- Europe secures another major customer in sleep AUD0.8m (USD0.5m)
- Company re-affirms FY25 guidance – sales more than \$55m and EBITDA about \$5m

Compumedics Limited (ASX: CMP) a global medical device company that develops, manufactures and commercialises diagnostic technology for sleep, brain, and ultrasonic blood flow monitoring is pleased to advise that the Company's Q1 trading result for the USA business is further evidence of the return to growth in this key market. Further, the Company has taken another significant order in Europe, this time in sleep. The sale is for a significant customer in Poland and was won against all major competitors.

In the USA based business, sales orders for the first quarter are running 136% higher than at the same time last year, with the sleep business leading the growth and with Somfit sales now trending towards \$1.0m in this key market. Sales momentum is continuing to build and with new sales resources coming on board, in line with our stated USA strategy, we are well placed to accelerate that growth over the remainder of FY25.

Sales momentum is also evident in the European business where another major tender has been secured for a leading sleep customer in Poland against all major competitors in the space. The sale is for about AUD0.8m (USD0.5m). The tender continues to build our business base in Europe with Compumedics having a strong presence in France and Germany from its offices there and from which to build business further throughout Europe.

For personal use only

About Compumedics Limited

Compumedics Limited [ASX: CMP] is a medical device company that develops, manufactures, and commercialises diagnostic technology for sleep, brain, and ultrasonic blood flow monitoring applications. The Company owns Neuroscan, based in the US, and DWL Elektronische GmbH, based in Germany. In conjunction with these two subsidiaries, Compumedics has a broad international reach, including the Americas, Australia and Asia Pacific, Europe, and the Middle East.

Executive Chairman Dr. David Burton founded Compumedics in 1987. The same year, the Company successfully designed and installed the first fully computerised Australian sleep clinic at Epworth Hospital in Melbourne. Following this early success, Compumedics focused on developing products for the growing international sleep clinic and home monitoring markets.

Compumedics listed on the Australian Securities Exchange in 2000. Over the years, Compumedics has received numerous awards, including Australia's Exporter of the Year, and has been recognised as a Top 100 Innovator by both German and Australian Governments.

For further information, please contact:

Dr. David Burton
Executive Chairman, CEO
P: +61 3 8420 7300
F: +61 3 8420 7399

David Lawson
Director, CFO
P: + 61 3 8420 7300
F: +61 3 8420 7399

Authorised for lodgement by Compumedics Limited's Board of Directors